Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 2, 2018
Event Date: September 27, 2018
Context: The Company entered into a Second Amendment to a material definitive lease agreement for its principal executive offices located at 101 Main Street, Cambridge, Massachusetts.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of a specific contractual agreement.
| Item | Details |
|---|---|
| Lease Term Extension | Extended by 5 years through March 31, 2024 |
| Option to Extend | Company has an option to extend for an additional 5 years |
| Annual Rent (Starting April 2019) | $2.1 million for the first 12 months |
| Rent Escalation | 2.0% annual increase thereafter |
| Leased Space | Approximately 23,350 square feet (10th floor) |
Material Changes Versus Prior Period
The material change is the extension of the lease term. Previously, the lease was set to expire on March 31, 2019. Under the Second Amendment, the term is now extended to March 31, 2024. The rent structure changes beginning in April 2019 to the new fixed annual amount with specified escalations.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the description of the Second Amendment is not complete and is qualified by reference to the full text of the agreement, which is expected to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2018.
Risks/Contingencies: The filing does not explicitly list new risks or contingencies beyond the commitment to the extended lease obligations.
Key Facts for Investor Verification
- Verify the total committed lease obligation over the extended term (2019–2024) including the 2.0% annual escalations.
- Confirm the impact of the new rent structure on the Company's operating expenses in the upcoming fiscal quarters.
- Review the full text of the Second Amendment in the subsequent Form 10-Q filing for any additional covenants or termination clauses not summarized here.
- Assess whether the 23,350 square feet remains adequate for the Company's operational needs through 2024.